WWW - Posts tagged OGXI at BloggingStocks

OGXI posts

OncoGenex (OGXI): Biotech Targets Cancer Treatments

Posted Apr 6th 2011 10:00AM by Steven Halpern (RSS feed)
Filed under: Newsletters, Teva Pharm Indus ADR (TEVA), Stocks to Buy

"OncoGenex Pharmaceuticals (OGXI) recently released their fourth quarter and year end 2010 financial results; during the conference call they discussed updates in their development programs and provided an outlook for 2011," notes biotech specialist John McCamant.

The editor of the Medical Technology Stock Letter continues, "The company reported a Q4 2010 net loss of $2.8 million or ($0.26) per share compared to Q4 2009 net profit of $3.9 million or $0.70 per share.

"OGXI finished the year in a solid position financially with $85.6 million in cash. The company expects to end 2011 with $50-$54 million on the balance sheet and use $31-$35 million in operating cash. They appear to have enough cash to fund operations into 2014.

Continue reading OncoGenex (OGXI): Biotech Targets Cancer Treatments

Analyst upgrades, downgrades and initiations: AAPL, COST, HPQ, JACK, MOS, NVLS, WMT ...

Posted Sep 21st 2009 12:00PM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Apple Inc (AAPL), Hewlett-Packard (HPQ), Wal-Mart (WMT), Costco Wholesale (COST), Analyst Initiations

Analyst upgrades:

Roth Capital upgraded MicroStrategy (NASDAQ: MSTR) to Buy from Hold and raised its target to $90 from $70, citing encouraging Q2 results, new product cycle catalysts, a lift from Europe, and cost reductions.
William Blair upgraded Costco (NASDAQ: COST) to Outperform from Market Perform after meeting with management as it believes sales and earnings could beat expectations over the next year.
Credit Suisse upgraded Novellus (NASDAQ: NVLS) to Outperform from Neutral and raised its target to $29 from $23. The firm cites higher Samsung capex forecast, high leverage, and low expectations.
Home Properties (NYSE: HME) and Equity Residential (NYSE: EQR) were upgraded to Outperform from Market Perform at FBC Capital, while Douglas Emmett (NYSE: DEI) and Duke Realty (NYSE: DRE) were raised to Market Perform from Underperform.
Agilent (NYSE: A) was upgraded to Overweight from Equal Weight at Barclays.
Cytec Industries (NYSE: CYT) was upgraded to Buy from Hold at KeyBanc.